Protara Therapeutics, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.32
- 52-Week Range
- $2.09 – $7.82
- Market Cap
- $144.07M
- P/E (TTM)
- —
- EPS (TTM)
- -1.39
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.99
- PEG Ratio
- —
- Return on Equity
- -57.40%
- Return on Assets
- -35.35%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 9.01
- Debt/Equity
- 0.02
- Total Debt
- $2.44M
- Free Cash Flow
- $-43.87M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $19.46M
Market Snapshot
About
Protara Therapeutics is a clinical-stage biopharmaceutical company developing transformative therapies for people with cancer and rare diseases. The company focuses on IV Choline Chloride for intestinal failure associated liver disease and TARA-002 for lymphatic malformations. Protara is advancing precision medicine approaches for underserved patient populations.